Nov 8th, 2020
Discover the latest research with Meet the Trialist
Meet the Trialist is a series of virtual conversations discussing current discoveries and up-to-date data in clinical trials.
These conversations take place from 4-4:45 p.m. on all five days of Scientific Sessions 2020.
Friday, Nov. 13
Session 1
- Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: The Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) Trial
- The Vital Rhythm Trial: Omega-3 Fatty Acid and Vitamin D Supplementation in the Primary Prevention of Atrial Fibrillation
Session 2
- Aspirin Alone and in Combination With a Polypill in Cardiovascular Disease Primary Prevention: Results From the International Polycap Study (TIPS)-3
- Prevalence and Prediction of Coronary Artery Disease in the General Population: Results From the Swedish Cardiopulmonary Bioimage Study (SCAPIS)
Saturday, Nov. 14
Session 3
- Ticagrelor Versus Clopidogrel in Elective Percutaneous Coronary Intervention: The Alpheus Trial
- Oral Anti-xa Anticoagulation After Trans-aortic Valve Implantation for Aortic Stenosis: The Randomized Atlantis Trial (Invited but not confirmed)
Sunday, Nov. 15
Session 4
- STRENGTH Trial: Cardiovascular Outcomes With Omega-3-Carboxylic Acids in Patients With High Vascular Risk and Atherogenic Dyslipidemia
- Effects of N-3 Fatty Acid Supplements on Clinical Outcome After Myocardial Infarction in the Elderly: Results of the OMEMI Trial
Session 5
- A Three-arm N-of-1 Trial with Statin-, Placebo- and Tablet-Free Periods, to Verify Side Effects and Identify Their Cause: The SAMSON Trial
- The Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia
Monday, Nov. 16
Session 6
- Enhanced Monitoring for Atrial Fibrillation Following Cardiac Surgery: Primary Results of the SEARCH-AF Cardiolink Randomized Trial
- Early Invasive Intervention for Atrial Fibrillation
Session 7
- Rivaroxaban Versus Warfarin in Patients With Bioprosthetic Mitral Valves and Atrial Fibrillation or Flutter: Primary Results From the RIVER Randomized Trial
- One-Month Dual Antipletelet Therapy Followed by Aspirin Monotherapy After Drug-Eluting Stent Implantation
Tuesday, Nov. 17
Session 8
- Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
- Ticagrelor Added to Aspirin in Acute Ischemic Stroke or TIA of Atherosclerotic Origin
Session 9
- High Dose Versus Standard Dose Influenza Vaccine in Patients with High-Risk Cardiovascular Disease: Results From the Invested Trial
- SCORED: Sotagliflozin in Patients With Diabetes and Chronic Kidney Disease
